Targeting the TrkB‐SH2B2 axis, in conjunction with epigenetic regulation and multimodal interventions, holds promise for disrupting the vicious cycle of smoking‐induced white matter damage and depression. Here, NTRK2 is linked to depressive symptom measurement.